Roche Has Room to Run

Long winning streak aside, there are lots of reasons to like Roche Holding. Among them: the Swiss drugmaker will continue to benefit from its 56% stake in Genentech. Genentech stock is now valued at 50 times this year's forecast earnings, and employee stock-option costs could become a drain on...

Full description

Saved in:
Bibliographic Details
Published in:Barron's 2006-04, Vol.86 (15), p.15
Main Author: Albert, Bill
Format: Article
Language:English
Subjects:
Cancer
Market potential
Pharmaceutical industry
Stock prices
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Long winning streak aside, there are lots of reasons to like Roche Holding. Among them: the Swiss drugmaker will continue to benefit from its 56% stake in Genentech. Genentech stock is now valued at 50 times this year's forecast earnings, and employee stock-option costs could become a drain on cash flow. For those able to buy the Swiss stock, Roche remains a safer way to enjoy biotech's breakthroughs. One of the few recent disappointments for Roche has been its diagnostic business.
ISSN:1077-8039